Former Covidien IRO Cole Lannum on his job transition to Mallinckrodt and the new scrutiny over specialty pharmaceuticals
Cole Lannum, senior vice president of investor strategy at Covidien spin-off Mallinckrodt, discusses the challenges brought on by the changing environment for the specialty pharmaceuticals sector. The multiple awards winner gives his top tip for IROs: treat investors like customers, not adversaries.
Staff Writers
The staff writers on IR magazine are from our team of highly experienced journalists.
